Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on BDRX SEC Filings - Biodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan

BDRX SEC Filings - Biodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms  Stock Titan

BDRX SEC Filings - Biodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan

Click here to get full coverage on Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now  Nasdaq

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq

Click here to get full coverage on BDRX.O's 29% Spike: Technical Triggers and Market Dynamics Unveiled - AInvest

BDRX.O's 29% Spike: Technical Triggers and Market Dynamics Unveiled  AInvest

BDRX.O's 29% Spike: Technical Triggers and Market Dynamics Unveiled - AInvest

Click here to get full coverage on BDRX Stock Soars: Time to Invest? - StocksToTrade

BDRX Stock Soars: Time to Invest?  StocksToTrade

BDRX Stock Soars: Time to Invest? - StocksToTrade

Click here to get full coverage on Results of Annual General Meeting | BDRX Stock News - GuruFocus

Results of Annual General Meeting | BDRX Stock News  GuruFocus

Results of Annual General Meeting | BDRX Stock News - GuruFocus

Click here to get full coverage on Biodexa Shareholders to Vote on Major Share Restructuring Plan - Key Details Inside - Stock Titan

Biodexa Shareholders to Vote on Major Share Restructuring Plan - Key Details Inside  Stock Titan

Biodexa Shareholders to Vote on Major Share Restructuring Plan - Key Details Inside - Stock Titan

Click here to get full coverage on BDRX.O's 15% Plunge: A Technical Sell-Off or Silent Sector Shift? - AInvest

BDRX.O's 15% Plunge: A Technical Sell-Off or Silent Sector Shift?  AInvest

BDRX.O's 15% Plunge: A Technical Sell-Off or Silent Sector Shift? - AInvest

Click here to get full coverage on Biodexa Pharmaceuticals (BDRX) Prepares for Phase 3 Study with Brand Name Serenta | BDRX Stock News - GuruFocus

Biodexa Pharmaceuticals (BDRX) Prepares for Phase 3 Study with Brand Name Serenta | BDRX Stock News  GuruFocus

Biodexa Pharmaceuticals (BDRX) Prepares for Phase 3 Study with Brand Name Serenta | BDRX Stock News - GuruFocus

Click here to get full coverage on Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan

Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM  Stock Titan

Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan

Click here to get full coverage on Result of General Meeting | BDRX Stock News - GuruFocus

Result of General Meeting | BDRX Stock News  GuruFocus

Result of General Meeting | BDRX Stock News - GuruFocus

Click here to get full coverage on Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions - Stock Titan

Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions  Stock Titan

Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions - Stock Titan

Click here to get full coverage on Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients - Stock Titan

Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients  Stock Titan

Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients - Stock Titan

Click here to get full coverage on Biodexa Secures Full Shareholder Approval for Share Value Reset and Enhanced Director Authority - Stock Titan

Biodexa Secures Full Shareholder Approval for Share Value Reset and Enhanced Director Authority  Stock Titan

Biodexa Secures Full Shareholder Approval for Share Value Reset and Enhanced Director Authority - Stock Titan

Click here to get full coverage on Biodexa Secures $22M for Rare Disease Drug Trial: Phase 3 FAP Study Launches in 30 Global Sites - Stock Titan

Biodexa Secures $22M for Rare Disease Drug Trial: Phase 3 FAP Study Launches in 30 Global Sites  Stock Titan

Biodexa Secures $22M for Rare Disease Drug Trial: Phase 3 FAP Study Launches in 30 Global Sites - Stock Titan

Click here to get full coverage on BDRX - Biodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan

BDRX - Biodexa Pharmaceuticals plc Latest Stock News & Market Updates  Stock Titan

BDRX - Biodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Biodexa Special Resolution Falls 4% Short: Chairman Promises New Fundraising Proposals - Stock Titan

Biodexa Special Resolution Falls 4% Short: Chairman Promises New Fundraising Proposals  Stock Titan

Biodexa Special Resolution Falls 4% Short: Chairman Promises New Fundraising Proposals - Stock Titan

Click here to get full coverage on Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment - Stock Titan

Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment  Stock Titan

Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment - Stock Titan

Click here to get full coverage on FDA Clears Biodexa's Phase 3 Protocol for Rare Disease Drug eRapa - Stock Titan

FDA Clears Biodexa's Phase 3 Protocol for Rare Disease Drug eRapa  Stock Titan

FDA Clears Biodexa's Phase 3 Protocol for Rare Disease Drug eRapa - Stock Titan

Click here to get full coverage on Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan

Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells  Stock Titan

Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan

Click here to get full coverage on Biodexa Secures Fast Track Status for Rare Disease Drug with $25.5M Funded Trial - Stock Titan

Biodexa Secures Fast Track Status for Rare Disease Drug with $25.5M Funded Trial  Stock Titan

Biodexa Secures Fast Track Status for Rare Disease Drug with $25.5M Funded Trial - Stock Titan

Click here to get full coverage on What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - Nasdaq

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock  Nasdaq

What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - Nasdaq

Click here to get full coverage on Biodexa Secures Additional $3M Grant, Boosting Rare Disease Treatment Trial to $20M Total Funding - Stock Titan

Biodexa Secures Additional $3M Grant, Boosting Rare Disease Treatment Trial to $20M Total Funding  Stock Titan

Biodexa Secures Additional $3M Grant, Boosting Rare Disease Treatment Trial to $20M Total Funding - Stock Titan

Click here to get full coverage on Biodexa Pharmaceuticals Announces Successful AGM Resolutions - TipRanks

Biodexa Pharmaceuticals Announces Successful AGM Resolutions  TipRanks

Biodexa Pharmaceuticals Announces Successful AGM Resolutions - TipRanks

Click here to get full coverage on Results of Annual General Meeting - GlobeNewswire

Results of Annual General Meeting  GlobeNewswire

Results of Annual General Meeting - GlobeNewswire

Click here to get full coverage on BDRX Launches First Site for Serenta Trial in FAP Patients | BDR - GuruFocus

BDRX Launches First Site for Serenta Trial in FAP Patients | BDR  GuruFocus

BDRX Launches First Site for Serenta Trial in FAP Patients | BDR - GuruFocus

Click here to get full coverage on Shareholder Update | BDRX Stock News - GuruFocus

Shareholder Update | BDRX Stock News  GuruFocus

Shareholder Update | BDRX Stock News - GuruFocus

Click here to get full coverage on Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting - GlobeNewswire

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting  GlobeNewswire

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting - GlobeNewswire

Click here to get full coverage on BDRX Shows Unexpected Dip: What’s Next? - timothysykes.com

BDRX Shows Unexpected Dip: What’s Next?  timothysykes.com

BDRX Shows Unexpected Dip: What’s Next? - timothysykes.com

Click here to get full coverage on Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes - GlobeNewswire

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes  GlobeNewswire

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes - GlobeNewswire

Click here to get full coverage on Biodexa's 16% Plunge: Technical Sell-Off or Hidden Catalyst? - AInvest

Biodexa's 16% Plunge: Technical Sell-Off or Hidden Catalyst?  AInvest

Biodexa's 16% Plunge: Technical Sell-Off or Hidden Catalyst? - AInvest

Click here to get full coverage on Biodexa Pharmaceuticals’ Stock Skyrockets! What’s Happening? - StocksToTrade

Biodexa Pharmaceuticals’ Stock Skyrockets! What’s Happening?  StocksToTrade

Biodexa Pharmaceuticals’ Stock Skyrockets! What’s Happening? - StocksToTrade

Click here to get full coverage on Biodexa shareholders approve all resolutions at general meeting - Investing.com

Biodexa shareholders approve all resolutions at general meeting  Investing.com

Biodexa shareholders approve all resolutions at general meeting - Investing.com

Click here to get full coverage on Biodexa Pharmaceuticals Plans Share Capital Reorganization and New Share Allotment - TipRanks

Biodexa Pharmaceuticals Plans Share Capital Reorganization and New Share Allotment  TipRanks

Biodexa Pharmaceuticals Plans Share Capital Reorganization and New Share Allotment - TipRanks

Click here to get full coverage on Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) | BDRX Stock News - GuruFocus

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) | BDRX Stock News  GuruFocus

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) | BDRX Stock News - GuruFocus

Click here to get full coverage on Biodexa Pharmaceuticals Provides Shareholder Update and Advances eRapa Phase 3 Program - TipRanks

Biodexa Pharmaceuticals Provides Shareholder Update and Advances eRapa Phase 3 Program  TipRanks

Biodexa Pharmaceuticals Provides Shareholder Update and Advances eRapa Phase 3 Program - TipRanks

Click here to get full coverage on Biodexa's 17% Plunge: Technical Breakdown or Sector Sell-Off? - AInvest

Biodexa's 17% Plunge: Technical Breakdown or Sector Sell-Off?  AInvest

Biodexa's 17% Plunge: Technical Breakdown or Sector Sell-Off? - AInvest

Click here to get full coverage on Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 St - GuruFocus

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 St  GuruFocus

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 St - GuruFocus

Click here to get full coverage on Biodexa secures additional $3M for cancer drug trial - Investing.com

Biodexa secures additional $3M for cancer drug trial  Investing.com

Biodexa secures additional $3M for cancer drug trial - Investing.com

Click here to get full coverage on Biodexa Pharmaceuticals Announces Successful Passing of General Meeting Resolutions - TipRanks

Biodexa Pharmaceuticals Announces Successful Passing of General Meeting Resolutions  TipRanks

Biodexa Pharmaceuticals Announces Successful Passing of General Meeting Resolutions - TipRanks

Click here to get full coverage on BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView

BDRX Stock Price and Chart — NASDAQ:BDRX  TradingView

BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView

Click here to get full coverage on With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Yahoo Finance

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter  Yahoo Finance

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Yahoo Finance

Click here to get full coverage on Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP  GlobeNewswire

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire

Click here to get full coverage on Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study - The Globe and Mail

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study  The Globe and Mail

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study - The Globe and Mail

Click here to get full coverage on Biodexa Pharmaceuticals Secures Additional $3M Grant for eRapa Phase 3 Program - TipRanks

Biodexa Pharmaceuticals Secures Additional $3M Grant for eRapa Phase 3 Program  TipRanks

Biodexa Pharmaceuticals Secures Additional $3M Grant for eRapa Phase 3 Program - TipRanks

Click here to get full coverage on Result of General Meeting - GlobeNewswire

Result of General Meeting  GlobeNewswire

Result of General Meeting - GlobeNewswire

Click here to get full coverage on Biodexa Pharmaceuticals Receives FDA Fast Track for eRapa in FAP Treatment - TipRanks

Biodexa Pharmaceuticals Receives FDA Fast Track for eRapa in FAP Treatment  TipRanks

Biodexa Pharmaceuticals Receives FDA Fast Track for eRapa in FAP Treatment - TipRanks

Click here to get full coverage on Biodexa's eRapa: A Rare Opportunity in a Billion-Dollar Market - AInvest

Biodexa's eRapa: A Rare Opportunity in a Billion-Dollar Market  AInvest

Biodexa's eRapa: A Rare Opportunity in a Billion-Dollar Market - AInvest

Click here to get full coverage on Biodexa Pharmaceuticals sees cash runway into 1Q26 - Yahoo Finance

Biodexa Pharmaceuticals sees cash runway into 1Q26  Yahoo Finance

Biodexa Pharmaceuticals sees cash runway into 1Q26 - Yahoo Finance

Click here to get full coverage on Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use - GlobeNewswire

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use  GlobeNewswire

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use - GlobeNewswire

Click here to get full coverage on Biodexa Pharmaceuticals Advances Phase 3 eRapa Program with FDA Approval - TipRanks

Biodexa Pharmaceuticals Advances Phase 3 eRapa Program with FDA Approval  TipRanks

Biodexa Pharmaceuticals Advances Phase 3 eRapa Program with FDA Approval - TipRanks

Click here to get full coverage on Biodexa Pharmaceuticals unveils ‘Serenta’ as name for upcoming Phase 3 FAP study - TipRanks

Biodexa Pharmaceuticals unveils ‘Serenta’ as name for upcoming Phase 3 FAP study  TipRanks

Biodexa Pharmaceuticals unveils ‘Serenta’ as name for upcoming Phase 3 FAP study - TipRanks

Click here to get full coverage on Biodexa Announces Successful Appeal of Nasdaq Delisting - GlobeNewswire

Biodexa Announces Successful Appeal of Nasdaq Delisting  GlobeNewswire

Biodexa Announces Successful Appeal of Nasdaq Delisting - GlobeNewswire

Click here to get full coverage on Preliminary Results for the Year Ended 31 December 2024 - GlobeNewswire

Preliminary Results for the Year Ended 31 December 2024  GlobeNewswire

Preliminary Results for the Year Ended 31 December 2024 - GlobeNewswire

Click here to get full coverage on Biodexa’s 25% Surge: What’s Driving the Market? - timothysykes.com

Biodexa’s 25% Surge: What’s Driving the Market?  timothysykes.com

Biodexa’s 25% Surge: What’s Driving the Market? - timothysykes.com

Click here to get full coverage on Notice of General Meeting - GlobeNewswire

Notice of General Meeting  GlobeNewswire

Biodexa Pharmaceticals (BDRX)

Price Chart

Key Statistics

Technicals

About BDRX

Latest News

BDRX SEC Filings - Biodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq

BDRX.O's 29% Spike: Technical Triggers and Market Dynamics Unveiled - AInvest

Advanced Charts

Top Gainers

Top Losers